WANY
RARE icon

Wealthspire Advisors (New York)’s Ultragenyx Pharmaceutical RARE Stock Holding History

Wealthspire Advisors (New York)’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-4
Closed -$120 – 2444
2025
Q3 		$120 Buy
+4
New +$120 ﹤0.01% 2986

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Wealthspire Advisors (New York)'s RARE Position: Q4 2025 in Review

Wealthspire Advisors (New York) sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2025, closing a stake of 4 shares — an estimated $120 sold.

Wealthspire Advisors (New York) first reported a position in RARE in Q3 2025 and held it in 1 quarter. The position peaked at $120 in Q3 2025. 288 funds tracked by Wall St. Rank hold RARE as of Q4 2025.

  • Wealthspire Advisors (New York) reported no remaining Ultragenyx Pharmaceutical position as of Q4 2025 after selling out during the quarter.
  • Wealthspire Advisors (New York) sold 4 Ultragenyx Pharmaceutical shares in Q4 2025, an estimated $120.
  • Wealthspire Advisors (New York) first reported a position in Ultragenyx Pharmaceutical in Q3 2025 and held it in 1 quarter.
  • Wealthspire Advisors (New York)'s Ultragenyx Pharmaceutical position peaked at $120 in Q3 2025.
  • 288 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2025.

Based on Wealthspire Advisors (New York)'s 13F filing for Q4 2025, filed 13 Feb 2026.